Please assess the completion status of the following clinical trial:

Trial Title: Pazopanib for Metastatic Alveolar Soft Part Sarcoma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Key Inclusion Criteria:~* Histologically confirmed diagnosis of alveolar soft part sarcoma harboring TFE3 fusion at stage IV or at relapse~* Age ≥ 18 years~* Eastern Cooperative Oncology Group (ECOG) performance status of 0-2~* Measurable lesion defined by RECIST v1.1~* Chemo-naïve or prior chemotherapies~* Adequate organ function~Exclusion Criteria:~* Prior malignancies~* Active CNS disease~* High-risk for gastrointestinal bleeding~* Significant cardiovascular disease~* Uncontrolled hypertension~* Bleeding diathesis

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Pazopanib (Type: EXPERIMENTAL): Pazopanib 800mg po qd until disease progression

Based on this trial design, predict the completion outcome and termination type (if applicable).